As 2023 ends and 2024 approaches, we are thankful for a year dedicated to new therapeutics for patients in need, and we look forward to a new year of continued innovations.
The end of a year always welcomes discussions about New Year’s resolutions and new opportunities in the coming year. While the best is yet to come, we cannot forget to celebrate an innovative year in dermatology. Clinical trials and FDA approvals for new therapeutics have been booming in 2023, and that has been evident in the numerous new agents added to dermatology professionals’ tool kit. Notable approvals from 2023 include secukinumab for hidradenitis suppurativa; Cabtreo for acne vulgaris; bimekizumab for moderate to severe plaque psoriasis; nivolumab for completely resected stage IIB/C melanoma; roflumilast cream 0.3% for pediatric psoriasis; VP-102 for molluscum contagiosum; ritlecitinib for alopecia areata; Restylane Eyelight for undereye hollows; beremagenege perpavec for dystrophic epidermolysis bullosa; Skinvive for skin smoothness; and numerous adalimumab biosimilars, including Hyrimoz, the Cyltezo autoinjector pen, Yuflyma, and Hadlima.
Updates in dermatology do not stop with FDA approvals. In recent news, the American Academy of Dermatology (AAD) published updated guidelines for the treatment of atopic dermatitis using phototherapy and systemic agents. Dermatology Times’ cover feature this month dives into the updates from AAD, what is new, what has changed since the previous 2014 guidelines, and how experts in inflammatory diseases are applying or continuing to use these therapies in their practice. You will learn important insights from Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM, FRCPC; and Mona Shahriari, MD.
Finally, Dermatology Times is wrapping up a year full of conference travel with highlights from the Society of Dermatology Physician Assistants 21st Annual Fall Dermatology Conference, held in Nashville, Tennessee; and the American College of Allergy, Asthma and Immunology Annual Scientific Meeting, held in Anaheim, California.
As 2023 ends and 2024 approaches, we are thankful for a year dedicated to new therapeutics for patients in need, and we look forward to a new year of continued innovations. To keep up with the latest updates in breaking news, treatment pearls, study data, and interviews with experts in the field, subscribe to Dermatology Times e-newsletters, follow us on social media, and email us at DTEditor@mmhgroup.com to share your insights about what you are looking forward to in 2024.